💯Jesse Fox aka Fatboy💯

🥹The coming soon posting arrived on Peptide Plugs for Eloralintide. This is up there with requests like a larger SS-31/Mots-C blend, which.... 😉 stay tuned. My discount link. peptideplugs.com/?ref=OPTIMIZED Code: Optimized Tons of other great options but for this, I want to focus on Elora. Before going in blind, actually see if this is something you want to research below. This is something I have been mentioning here and there, as a substitute for Cagri, if curious about the Amylin antagonism and its synergy with a GLP. I am personally looking to research with this, although the timing I haven't quite worked out yet, because I have no idea how to jam it inside my current ludicrous research protocol. Here are some differences we know so far and bit of DD I had stored up on it. --- ⭐️Eloralintide (LY3841136) — a selective amylin receptor agonist. Amylin is a hormone your pancreas releases along with insulin after you eat. It plays a key role in telling your brain you’re full, slowing how fast food leaves your stomach, and keeping post-meal glucagon from spiking too high. These effects help control appetite and how your body handles nutrients. Eloralintide is designed to mimic those natural amylin actions. The core benefits come from: -Stronger and more sustained feelings of satiety (you feel full longer and tend to eat less without as much mental effort). -Slowed gastric emptying, which prolongs the feeling of fullness after meals. -Reduced postprandial glucagon release, which can help with more stable glucose handling after eating. Because it works through the amylin pathway instead of the GLP-1 or glucagon pathways, it opens up real possibilities for people who want something mechanistically distinct — either as an alternative or potentially in combination with compounds like Retatrutide down the line. ⭐️Now here’s where it gets interesting compared to Cagrilintide. Cagrilintide was the first major long-acting amylin analog and it activates both amylin receptors and calcitonin receptors. That dual action delivers solid satiety and weight management effects, but for some people the broader receptor activity can come with more noticeable GI side effects or other tolerability trade-offs. Eloralintide was engineered to be highly selective for the amylin 1 receptor (AMY1R) while having minimal activity at the calcitonin receptor. This more targeted profile is the key difference. For people who tried Cagrilintide and found the side effects (especially GI-related) harder to manage, Eloralintide may offer a cleaner experience while still delivering the core amylin benefits of increased satiety and slowed gastric emptying. It’s not that Cagrilintide is “bad” — it was the pioneering compound in this class. Eloralintide is simply the next-generation version built with higher selectivity in mind, which appears to translate to a more favorable tolerability profile in the data released so far. Early clinical work also showed it was generally well tolerated, with the expected GI effects (nausea, etc.) that tend to improve with slower dose escalation — similar to other gut hormone agents, but often described as more manageable at equivalent effect levels. ❤️Another interesting signal: it tended to lower resting heart rate in studies, which goes in the opposite direction of most GLP-1-based compounds. Overall, Eloralintide represents a more refined tool in the amylin space. Same fundamental benefits (satiety, gastric slowing, glucagon modulation) delivered through a more selective mechanism that may make it easier for some people to tolerate long-term. ⭐️If you’ve had a rough time with Cagrilintide’s side effects but still like the idea of amylin-driven satiety and fullness, this one is worth watching closely. Different receptor profile, potentially better day-to-day experience.⭐️